Nav: Home

Administration budget proposal undermined by concurrent cuts

March 12, 2019

The White House budget proposal for 2020 recommends increases to the domestic HIV programs at the U.S. Centers for Disease Control and Prevention, the Health Resources and Services Administration and Indian Health Services that will be essential to keeping the administration's promise of ending our nation's HIV epidemic in the next decade. Deep cuts planned in the same proposal however, to the Medicaid program, to the National Institutes of Health, and U.S.-led global HIV responses, counter those increases and would gravely compromise efforts to eliminate new infections here, and, as the president said in his State of the Union Address "everywhere."

While the administration plan to end the U.S. epidemic recognizes that the treatment and prevention tools needed to stop transmissions exist now, just a little more than half of people with HIV are accessing treatment that is effective or consistent enough to suppress the virus, protect their health, and prevent transmission. As one result, nearly 40,000 people continue to become infected with the virus each year. The administration's plan, and the budget plan address the need for expanded treatment and prevention access to bring a 75 percent reduction in HIV transmissions by 2025, and a 90 percent reduction by 2030, by proposing $291 million in support for efforts through the CDC, the IHS, and HRSA, including through the Ryan White HIV/AIDS Program. Importantly, the proposal also includes $58 million for CDC to respond to the growing infectious diseases consequences of the opioid epidemic.

These welcome, while modest increases to programs that have largely been flat-funded for a decade however, are insufficient to achieve the goal of ending the HIV epidemic. Coupled with policies that would undermine broader public health and health care systems, the potential impacts of the increases are further weakened. The president's renewed call for repealing the Affordable Care Act including the Medicaid expansion and block granting Medicaid would greatly setback access to healthcare for people living with HIV, hobbling efforts to end the American epidemic. Flat funding for viral hepatitis and sexually transmitted diseases programs will result in these epidemics continuing unabated.

Significant cuts proposed to the National Institutes of Health, would stifle biomedical research innovation. Deep cuts to the President's Emergency Plan for AIDS Relief and to the U.S. contribution to the Global Fund to Fight AIDS, Tuberculosis and Malaria would gravely weaken American leadership of HIV responses and reverse progress in reducing new HIV infections worldwide.

Ending the HIV epidemic will require affordable, comprehensive health coverage that offers access to high-quality providers and services, and a robust and sustainable health care system. Ensuring that progress against HIV is sustained will require continued, committed investment in biomedical research and innovation. The goal the president has set won't be accomplished without continued investment in programs critical to controlling the epidemic globally.

While the discretionary funding increases outlined in the budget are an important start to increase HIV screening and improve access to HIV prevention and care, in its totality the administration's proposal would represent a serious setback to efforts to end the HIV epidemic in the U.S. and around the world. We look forward to working with Congress to advance funding bills that will support the resources and policies needed to make a serious commitment to ending the HIV epidemic.
-end-


Infectious Diseases Society of America

Related Hiv Articles:

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.
The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.
Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.
NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
First ever living donor HIV-to-HIV kidney transplant
For the first time, a person living with HIV has donated a kidney to a transplant recipient also living with HIV.
The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.
Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.
HIV RNA expression inhibitors may restore immune function in HIV-infected individuals
Immune activation and inflammation persist in the majority of treated HIV-infected individuals and is associated with excess risk of mortality and morbidity.
HIV vaccine elicits antibodies in animals that neutralize dozens of HIV strains
An experimental vaccine regimen based on the structure of a vulnerable site on HIV elicited antibodies in mice, guinea pigs and monkeys that neutralize dozens of HIV strains from around the world.
State-of-the-art HIV drug could curb HIV transmission, improve survival in India
An HIV treatment regimen already widely used in North America and Europe would likely increase the life expectancy of people living with HIV in India by nearly three years and reduce the number of new HIV infections by 23 percent with minimal impact on the country's HIV/AIDS budget.
More Hiv News and Hiv Current Events

Top Science Podcasts

We have hand picked the top science podcasts of 2019.
Now Playing: TED Radio Hour

In & Out Of Love
We think of love as a mysterious, unknowable force. Something that happens to us. But what if we could control it? This hour, TED speakers on whether we can decide to fall in — and out of — love. Guests include writer Mandy Len Catron, biological anthropologist Helen Fisher, musician Dessa, One Love CEO Katie Hood, and psychologist Guy Winch.
Now Playing: Science for the People

#543 Give a Nerd a Gift
Yup, you guessed it... it's Science for the People's annual holiday episode that helps you figure out what sciency books and gifts to get that special nerd on your list. Or maybe you're looking to build up your reading list for the holiday break and a geeky Christmas sweater to wear to an upcoming party. Returning are pop-science power-readers John Dupuis and Joanne Manaster to dish on the best science books they read this past year. And Rachelle Saunders and Bethany Brookshire squee in delight over some truly delightful science-themed non-book objects for those whose bookshelves are already full. Since...
Now Playing: Radiolab

An Announcement from Radiolab